JPRN-UMIN000007121已完成未知
Evaluation of safety and efficacy of eribulin for patients advanced or recurrent HER2 negative breast cancer who have been treated with anthracyclines and taxanes - KBC-SG1105
Kyushu Breast Cancer Study Group0 个研究点目标入组 50 人开始时间: 2012年1月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1 ineligible patients complicated with infectious diseases or who suspected infectious diseases with fever 2. diarrheal , ileus 3. GI bleeding 4.severe drug allergy 5. severe renal and/ or liver dysfunction 6.significant interstitial pneumonia or pulmonary fibrosis by chest radiograph 7.pleural effusion, peritoneal effusion 8.poorly controlled hypertension or diabetes mellitus 9.maintenance therapy with systemic corticosteroids 10.pregnant women or women with suspected pregnancy 11.patients who received blood transfusion, blood products or G-CSF within 7 days prior to this study 12.presence of the active other malignancies 13.severe psychiatric disorder 14 brain metastases 15.patients judged by the investigator to be unfit for the study
研究者
相似试验
未知
2 期
A study to evaluate the efficacy of Eribulin retreatment in HER2 negative Metastatic Breast Cancer patients - Phase II studyHER2-negative metastatic breast cancerJPRN-UMIN000027165Toho university30
尚未招募
不适用
Efficacy and safety of eribulin in combination with trastuzumab and pertuzumab for HER2-positive advanced breast cancerEligible patients were those with HER2-positive advanced breast cancer who had previously received trastuzumab (HER) + pertuzumab (PER) + taxanes and T-DM1, followed by HER + PER + eribulin.JPRN-UMIN000034477Keio University School of Medicine35
已完成
不适用
A Phase II Study of Eribulin Evaluating Efficacy and Safety as first or secondary line chemotherapy for advanced or metastatic breast cancer without HER2 overexpressingAdvanced or metastatic breast cancerJPRN-UMIN000009568General and Gastroenterological Surgery, Osaka Medical College35
已完成
2 期
Efficacy and safety of Eribulin as the first line therapy for advanced or recurrent breast cancer patients without HER2 overexpression.Advanced or metastatic breast cancerJPRN-UMIN000006086Dept. Surgical Oncology, Osaka City University Graduate School of Medicine35
招募中
不适用
Exploratory clinical study of eribulin followed by taxane for metastatic breast cancer patientsMetastatic breast cancerJPRN-UMIN000027527Yamaguchi University Graduate School of Medicine30